Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $2.8 billion.

  • UNITED THERAPEUTICS's Cash & Current Investments fell 16.80% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 billion, marking a year-over-year increase of 3.37%. This contributed to the annual value of $3.3 billion for FY2024, which is 9.11% up from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Cash & Current Investments of $2.8 billion as of Q3 2025, which was down 9.22% from $3.0 billion recorded in Q2 2025.
  • UNITED THERAPEUTICS's 5-year Cash & Current Investments high stood at $3.3 billion for Q3 2024, and its period low was $1.7 billion during Q1 2021.
  • Moreover, its 3-year median value for Cash & Current Investments was $3.0 billion (2024), whereas its average is $3.0 billion.
  • In the last 5 years, UNITED THERAPEUTICS's Cash & Current Investments spiked by 47.03% in 2022 and then decreased by 16.80% in 2025.
  • UNITED THERAPEUTICS's Cash & Current Investments (Quarterly) stood at $1.9 billion in 2021, then soared by 47.03% to $2.8 billion in 2022, then increased by 5.47% to $3.0 billion in 2023, then rose by 9.11% to $3.3 billion in 2024, then dropped by 16.80% to $2.8 billion in 2025.
  • Its Cash & Current Investments stands at $2.8 billion for Q3 2025, versus $3.0 billion for Q2 2025 and $3.3 billion for Q1 2025.